Telehealth: A winning weapon to face the COVID-19 outbreak for patients with pulmonary arterial hypertension.
COVID-19
Pulmonary arterial hypertension
Telecardiology
Telemedicine
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
26
05
2022
accepted:
12
06
2022
pubmed:
19
6
2022
medline:
21
9
2022
entrez:
18
6
2022
Statut:
ppublish
Résumé
COVID-19 pandemic severely affected national health systems, altering the modality and the type of care of patients with acute and chronic diseases. To minimize the risk of exposure to SARS-CoV2 for patients and health professionals, face-to-face visits were cancelled or postponed and the use of telemedicine was strongly encouraged. This reorganization involved especially patients with rare diseases needing periodic comprehensive assessment, such as pulmonary arterial hypertension (PAH). The paper reports a proposal of strategy adopted for patients followed at our PAH center in Rome, where patients management was diversified based on clinical risk according to the European Society of Cardiology/European Respiratory Society PH guidelines-derived score and the REVEAL 2.0 score. A close monitoring and support of these patients were made possible by policy changes reducing barriers to telehealth access and promoting the use of telemedicine. Synchronous/asynchronous modalities and remote monitoring were used to collect and transfer medical data in order to guide physicians in therapeutic-decision making. Conversely, the use of implantable monitors providing hemodynamic information and echocardiography-mobile devices wirelessly connecting was limited by the poor experience existing in this setting. Large surveys and clinical trials are welcome to test the potential benefit of the optimal balance between traditional PAH management and telemedicine opportunities. Italy was found unprepared to manage the dramatic effects caused by COVID-19 on healthcare systems. In this emergency situation telemedicine represented a promising tool especially in rare diseases as PAH, but was limited by its scattered availability and legal and ethical issues. Cohesive partnership of health care providers with regional public health officials is needed to prioritize PAH patients for telemedicine by dedicated tools.
Sections du résumé
BACKGROUND
COVID-19 pandemic severely affected national health systems, altering the modality and the type of care of patients with acute and chronic diseases. To minimize the risk of exposure to SARS-CoV2 for patients and health professionals, face-to-face visits were cancelled or postponed and the use of telemedicine was strongly encouraged. This reorganization involved especially patients with rare diseases needing periodic comprehensive assessment, such as pulmonary arterial hypertension (PAH).
MAIN BODY
The paper reports a proposal of strategy adopted for patients followed at our PAH center in Rome, where patients management was diversified based on clinical risk according to the European Society of Cardiology/European Respiratory Society PH guidelines-derived score and the REVEAL 2.0 score. A close monitoring and support of these patients were made possible by policy changes reducing barriers to telehealth access and promoting the use of telemedicine. Synchronous/asynchronous modalities and remote monitoring were used to collect and transfer medical data in order to guide physicians in therapeutic-decision making. Conversely, the use of implantable monitors providing hemodynamic information and echocardiography-mobile devices wirelessly connecting was limited by the poor experience existing in this setting. Large surveys and clinical trials are welcome to test the potential benefit of the optimal balance between traditional PAH management and telemedicine opportunities.
CONCLUSION
Italy was found unprepared to manage the dramatic effects caused by COVID-19 on healthcare systems. In this emergency situation telemedicine represented a promising tool especially in rare diseases as PAH, but was limited by its scattered availability and legal and ethical issues. Cohesive partnership of health care providers with regional public health officials is needed to prioritize PAH patients for telemedicine by dedicated tools.
Identifiants
pubmed: 35716991
pii: S1537-1891(22)00073-8
doi: 10.1016/j.vph.2022.107024
pmc: PMC9212864
pii:
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107024Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest R. Badagliacca received fees for participating in advisory boards and received benefits (travel and accommodation for scientific meetings) from Actelion, Bayer, Dompè, Ferrer, GSK, MSD. C.D. Vizza received fees for serving as a speaker, consultant and an advisory board member, from the following Companies: Actelion, Dompè, GSK, Italfarmaco, Lilly, Pfizer, United Therapeutics. The other authors reported no conflicts of interest.
Références
J Heart Lung Transplant. 2021 Mar;40(3):172-182
pubmed: 33414063
J Heart Lung Transplant. 2018 Mar;37(3):365-375
pubmed: 28912026
Eur Respir J. 2020 Sep 24;56(3):
pubmed: 32430422
Eur Respir Rev. 2014 Dec;23(134):476-87
pubmed: 25445946
Eur Respir J. 2017 Jun 1;49(6):
pubmed: 28572119
J Heart Lung Transplant. 2020 Aug;39(8):805-814
pubmed: 32381339
Ital Heart J. 2005 Oct;6(10):840-5
pubmed: 16270477
Am J Cardiovasc Dis. 2020 Jun 15;10(2):34-47
pubmed: 32685262
Prev Med. 1985 Nov;14(6):753-81
pubmed: 2418436
Eur Respir Rev. 2016 Dec;25(142):390-398
pubmed: 27903661
J Heart Lung Transplant. 2017 Aug;36(8):871-879
pubmed: 28579006
Regul Pept. 2005 Jan 15;124(1-3):187-93
pubmed: 15544858
Health Qual Life Outcomes. 2021 Aug 24;19(1):202
pubmed: 34429110
JACC Cardiovasc Imaging. 2020 Sep;13(9):2054-2056
pubmed: 32563644
Catheter Cardiovasc Interv. 2020 Aug;96(2):336-345
pubmed: 32311816
J Heart Lung Transplant. 2016 Nov;35(11):1321-1329
pubmed: 27241861
Eur Respir J. 2020 Sep 24;56(3):
pubmed: 32973075
J Heart Lung Transplant. 2017 Oct 2;:
pubmed: 29107544
J Heart Lung Transplant. 2020 Apr;39(4):310-320
pubmed: 32061507
Int J Cardiol. 2018 Oct 15;269:265-271
pubmed: 29921516
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Circ Heart Fail. 2015 Sep;8(5):905-13
pubmed: 26283292
Cardiovasc Res. 2022 Jun 22;118(7):1618-1666
pubmed: 34864876
Regul Pept. 2008 Nov 29;151(1-3):48-53
pubmed: 18796317
J Heart Lung Transplant. 2020 Dec;39(12):1389-1397
pubmed: 32933828
J Cardiopulm Rehabil. 2002 Jul-Aug;22(4):298-308
pubmed: 12202852
Chest. 2019 Dec;156(6):1176-1186
pubmed: 31265832
Eur Respir Rev. 2012 Mar 1;21(123):40-7
pubmed: 22379173
J Heart Lung Transplant. 2015 Mar;34(3):282-305
pubmed: 25682555
Curr Med Chem. 2021;28(32):6569-6590
pubmed: 33342402
BMJ Health Care Inform. 2020 Sep;27(3):
pubmed: 32928780
Chest. 2020 Feb;157(2):376-383
pubmed: 31563498
Eur J Prev Cardiol. 2019 Jan;26(1):86-93
pubmed: 30354746
Eur Respir J. 2022 Oct 6;60(4):
pubmed: 35301247
Vascul Pharmacol. 2005 Jun;43(1):36-9
pubmed: 15890561
J Law Med Ethics. 2019 Jun;47(2_suppl):39-42
pubmed: 31298126
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
JACC Cardiovasc Imaging. 2021 Jan;14(1):162-172
pubmed: 33129726
Pulm Circ. 2020 Jul 23;10(3):2045894020941682
pubmed: 32754309
Circ Heart Fail. 2010 Sep;3(5):580-7
pubmed: 20562255
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1484-1488
pubmed: 32250751
Int J Cardiol. 2017 Mar 1;230:53-58
pubmed: 28038821
Chest. 2012 Dec;142(6):1391-1398
pubmed: 22576635
J R Soc Med. 2010 Nov;103(11):442-6
pubmed: 20959351
Chest. 2015 Oct;148(4):1043-54
pubmed: 26066077
Am J Respir Crit Care Med. 2021 Feb 15;203(4):484-492
pubmed: 32857597
Eur Respir Rev. 2018 May 2;27(148):
pubmed: 29720508
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545971
Ann Intern Med. 2011 Jul 5;155(1):33-8
pubmed: 21727291
J Am Coll Cardiol. 2010 Jul 27;56(5):372-8
pubmed: 20650358
J Cardiovasc Nurs. 2016 May-Jun;31(3):236-44
pubmed: 25774841
Int J Cardiol. 2020 Feb 15;301:183-189
pubmed: 31806280
Cardiology. 2012;121(2):76-82
pubmed: 22433455
J Clin Med. 2021 Dec 24;11(1):
pubmed: 35011825
J Cardiovasc Electrophysiol. 2020 Nov;31(11):2814-2823
pubmed: 32954600
Ann Am Thorac Soc. 2021 Jan;18(1):34-43
pubmed: 32926635
Chest. 2019 Aug;156(2):323-337
pubmed: 30772387